ORGENESIS INC (ORGS)

US68619K2042 - Common Stock

2.11  -1.13 (-34.84%)

After market: 2.25 +0.14 (+6.64%)

ORGENESIS INC

NASDAQ:ORGS (10/18/2024, 8:00:02 PM)

After market: 2.25 +0.14 (+6.64%)

2.11

-1.13 (-34.84%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-52.75%
Sales Q2Q%-96.47%
CRS1.25
6 Month-57.88%
Overview
Earnings (Last)08-13 2024-08-13/bmo
Earnings (Next)11-11 2024-11-11/bmo
Ins Owners790.6%
Inst Owners3.18%
Market Cap10.06M
Shares4.77M
PEN/A
Fwd PE3.39
Dividend YieldN/A
Analysts82.86
Short Float %0.49%
Short Ratio0.12
IPO07-01 2010-07-01
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ORGS Daily chart

Company Profile

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 146 full-time employees. The company went IPO on 2010-07-01. The firm focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. The company operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Company Info

ORGENESIS INC

20271 Goldenrod Lane

Germantown MARYLAND 20876

P: 14806596404

CEO: Vered Caplan

Employees: 146

Website: https://www.orgenesis.com/

ORGS News

News Imagea month ago - Orgenesis Inc.Orgenesis Provides Third Quarter 2024 Business Update

GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...

News Image3 months ago - Orgenesis Inc.Orgenesis Announces Reverse Stock Split

GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”) today announced that its Board of...

News Image4 months ago - Orgenesis Inc.Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Orgenesis’ CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine...

News Image4 months ago - Orgenesis Inc.Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into...

News Image4 months ago - InvestorPlaceORGS Stock Earnings: Orgenesis Reported Results for Q2 2024

Orgenesis just reported results for the second quarter of 2024.

News Image4 months ago - BusinessInsiderORGS Stock Earnings: Orgenesis Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Orgenesis (NASDAQ:ORGS) just reported results for the second quarter of 2024.Or...

ORGS Twits

Here you can normally see the latest stock twits on ORGS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example